CNBC · General

AstraZeneca stock jumps 4% after surprise trial win for lung disease drug where rivals have failed

· By Elsa Ohlen
Story summary

AstraZeneca's stock jumped as much as 4% after Britain's most valuable company said its experimental lung disease medicine met its target in two late-stage clinical trials.

Read at CNBC

Opens the original publisher in a new tab. Full articles belong to their publishers; a subscription may be required.

Your local edition.

Choose a timezone for story timestamps and date filters.